What Can4Med does

Can4Med, legally known as Curaleaf Poland S.A., is a licensed pharmaceutical wholesaler operating in Poland, specializing in the distribution of medical cannabis products for prescription. The company was rebranded following its integration into Curaleaf International, a multi-jurisdictional cannabis operator with operations across the UK, Spain, Portugal, Germany, Poland, Sweden, Turkey, Canada, and Australia. Curaleaf Poland holds a specific pharmaceutical wholesale license for narcotics of group I-N, authorizing it to distribute dried cannabis flower and cannabis extract products containing Δ9-trans-tetrahydrocannabinol (THC) and cannabinoids for prescription in Poland. All products distributed are manufactured under Good Manufacturing Practice (GMP) conditions and hold marketing authorization in Poland.

The company's business model is B2B pharmaceutical wholesale, supplying medical cannabis products directly to licensed pharmacies across Poland that dispense them to patients holding valid prescriptions. Curaleaf Poland works with multiple licensed producers to maintain a broad product range and to facilitate pharmacy procurement of controlled substances. Orders are placed via direct phone (+48 71 795 33 25) and email contact, with the CEO and COO serving as named points of contact — indicating a sales-led, relationship-driven GTM motion rather than a digital self-service channel. Distribution is exclusively domestic to Poland, with headquarters in Wrocław (ul. Wałbrzyska 17/1, 50-413 Wrocław) and an additional operational facility in Szczodre (ul. Tulipanowa 5, 55-095 Szczodre) operated as "Farmaceutyczna Curaleaf Poland."

The company's underlying "technology" is the regulatory and supply-chain infrastructure required for narcotics distribution: acquisition, registration, marketing authorization, and ongoing pharmacovigilance (including an adverse event reporting function on the corporate site) of cannabis-based medicines within Poland's post-2017 legal framework. Revenue is generated through wholesale margins on pharmaceutical product sales to pharmacies, with B2B pricing negotiated directly and not publicly disclosed. The company's market opportunity is the eligible Polish patient population, calculated at several hundred thousand patients since cannabis legalization in 2017.

Name

Can4Med

Legal name

Curaleaf Poland S.A.

Website

https://can4med.pl

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Curaleaf Poland S.A. (formerly Can4Med) is a licensed Polish pharmaceutical wholesaler distributing GMP-certified medical cannabis products, including dried flower and THC-containing extracts, directly to pharmacies across Poland as part of Curaleaf International's pan-European cannabis network.

Ownership category

akta.pro rank

Headquarters

HQ city

Wroclaw

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Compliance/Regulatory, Marketing or Sales

Revenue model

1. Pharmaceutical Wholesale Distribution: Revenue generated through wholesale distribution of medical cannabis products to pharmacies in Poland. As a licensed pharmaceutical wholesaler for medicinal products and narcotics, the company acquires, registers, and distributes cannabis-based medicines, earning margins on product sales through established pharmacy distribution networks.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Curaleaf Poland S.A. (formerly Can4Med) is a licensed pharmaceutical wholesaler based in Wrocław, Poland that distributes GMP-certified medical cannabis products — including dried flower and extracts containing THC — to pharmacies across Poland under narcotics group I-N licensing. The company operates as the Polish arm of Curaleaf International, supplying regulated cannabis-based medicines to licensed dispensing pharmacies.

Product overview

Can4Med (now Curaleaf Poland S.A.) operates as a pharmaceutical wholesaler specializing in medical cannabis distribution. The company's core offering consists of dried cannabis flower and cannabis extract products containing THC and cannabinoids, which are manufactured under GMP (Good Manufacturing Practice) conditions and distributed to pharmacies throughout Poland. The company provides facilitated access for pharmacies and licensed producers to a wide range of medical cannabis products, handling acquisition, registration, and distribution of cannabis-based medicines for medical use.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Cannabis Dried Flower
• Medical Cannabis Extracts

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Licensed ProducerscoreOthersStrategic collaboration with licensed producers to provide pharmacies with fast and supported access to medical cannabis products. The company works with multiple producers to offer an established and wide range of product strains and formats, continuously expanding product options and availability in Poland.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Canopy Growth Corporation: Global cannabis leader that acquired Polish medical cannabis producer HemPoland. Operates across cultivation, extraction, and distribution in multiple European countries, overlapping directly with Curaleaf Poland through Polish-market presence and broader European wholesale activity.
• Aurora Cannabis: Canadian-headquartered medical cannabis producer with European distribution operations. Comparable as a multi-country wholesale player competing for the same GMP-certified product supply and European pharmacy customers as Curaleaf Poland.
• Tilray Brands: Large multi-jurisdiction cannabis operator with pharmaceutical-grade medical cannabis distribution across Europe, including Germany and other EU markets. Competes for the same licensed-pharmacy customers and supplier relationships that drive Curaleaf Poland's business.

Direct peers

• Demecan: German-licensed producer and distributor of medical cannabis flowers and extracts. Closely comparable in product mix (GMP-certified medical cannabis) and go-to-market (B2B wholesale to pharmacies) within the European medical cannabis value chain.
• Four 20 Pharma: German medical cannabis distributor that is a sister company under the same Curaleaf International parent. Operates a comparable B2B wholesale-to-pharmacy model for medical cannabis in a larger European market, making it the closest functional and strategic peer to Curaleaf Poland.
• Curaleaf Portugal: Portuguese medical cannabis operation also under the Curaleaf International umbrella. Engaged in cannabis cultivation, processing, and distribution, sharing the same corporate parent, supplier relationships, and regulatory playbook as Curaleaf Poland.

Emerging players

• Cellen Therapeutics: UK-based medical cannabis manufacturer and distributor focused on cannabis-based medicines. Similar in operating model (licensed manufacturing plus wholesale distribution) within Europe's regulated medical cannabis market.
• Sanity Group: Berlin-based medical cannabis company with German cultivation and distribution. Comparable in stage and operating model (B2B medical cannabis distribution into a regulated European market) but focused on Germany rather than Poland.
• Cannaray Therapeutics: UK-based medical cannabis distributor offering both branded products and B2B wholesale. Comparable as a European-focused medical cannabis wholesaler with similar regulatory-led go-to-market, though operating in a different national market.

Others

• Curaleaf Inc. US-listed parent group of Curaleaf International, of which Curaleaf Poland is ultimately a subsidiary. Relevant as the ultimate corporate parent and as a global medical cannabis operator whose strategic priorities shape Curaleaf Poland's positioning and capital access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xx.com/curaleafint
• LinkedInlinkedin.com/company/can4med

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Can4Med